Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCT · Real-Time Price · USD
17.77
+0.85 (5.02%)
At close: Feb 21, 2025, 4:00 PM
17.75
-0.02 (-0.11%)
After-hours: Feb 21, 2025, 7:10 PM EST
ARCT Employees
Arcturus Therapeutics Holdings had 180 employees as of December 31, 2023. The number of employees increased by 10 or 5.88% compared to the previous year.
Employees
180
Change (1Y)
10
Growth (1Y)
5.88%
Revenue / Employee
$891,106
Profits / Employee
-$348,017
Market Cap
481.34M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
ARCT News
- 8 days ago - European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine - PRNewsWire
- 18 days ago - Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate - Business Wire
- 22 days ago - Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19 - Business Wire
- 22 days ago - Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference - Business Wire
- 6 weeks ago - Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial - Business Wire
- 6 weeks ago - Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency - Business Wire
- 2 months ago - Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 3 months ago - Arcturus Therapeutics to Attend Upcoming Investor Conferences - Business Wire